You are here: Industry Insights > Market News > EU reaches supply deal with Moderna for 160 mn doses of COVID-19 vaccine

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

EU reaches supply deal with Moderna for 160 mn doses of COVID-19 vaccine

expresspharmaNovember 25, 2020

Tag: COVID-19 Vaccine , EU , Moderna

Favorites

The European Commission (EU) has reached a deal with US biotech firm Moderna for the supply of its COVID-19 vaccine candidate, an EU official told Reuters.

The president of the EU, Ursula von der Leyen informed that the deal is for the supply of up to 160 million doses of its COVID-19 vaccine candidate.

The deal will be formally approved by the EU executive on Wednesday, she said.

Previous:AIOCD asks members to strengthen cold chain capabilities for COVID-19 vaccines

Next:Micro Labs launches anti-diabetic drug combo, Dapagliflozin plus Metformin

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

Biotech NewswireMay 10, 2024

Nucleic Acid Medicines Manufacture, Round 2 call.

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Biotech NewswireMay 09, 2024

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

Biotech NewswireMay 09, 2024

EU reaches supply deal with Moderna for 160 mn doses of COVID-19 vaccine | Pharmasources.com

On the Path to Net Zero: Vetter Achieves New Sustainability Goals in 2023

Biotech NewswireMay 09, 2024

Alongside its dynamic growth, Vetter announced that it achieved its sustainability goals for 2023.

EU reaches supply deal with Moderna for 160 mn doses of COVID-19 vaccine

Related News

Touchlight Genetics and the National Physical Laboratory (NPL) Awarded Grant to Develop Novel Gene-Length Single-Stranded Genome Editing Template

First Commercial Cell and Gene Therapy Product Manufactured at Minaris Regenerative Medicine in Allendale, NJ.

Glucagon-like peptide-1 (GLP-1) Receptor Agonist Semaglutide in an Oleogel Formulation Using the BrainDos™ Technology Significantly Increases Drug Delivery into Cells

On the Path to Net Zero: Vetter Achieves New Sustainability Goals in 2023

You may like